Summon to Annual General Meeting in Dicot Pharma May 6 at 17.00

Uppsala, Sweden, April 3, 2025. The shareholders of Dicot Pharma AB, (reg. no. 559006-3490), are hereby invited to the Annual General Meeting to be held on Tuesday May 6, 2025, at 17.00 at Advokatfirman Lindahl at Vaksalagatan 10, Uppsala. Sandwiches, coffee and drinks will be served from 16.30.

The meeting is open for shareholders. Information on how to register, the agenda, and a description of proposals is available at www.dicotpharma.com.

This is a short summary in English, for the full summon in Swedish please refer to the website.

Uppsala in April, 2025

Dicot Pharma AB
The Board of Directors

For further information, please contact:
Elin Trampe, CEO
Phone: +46 72 502 10 10
E-mail: [email protected]

About Dicot Pharma AB
Dicot Pharma is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to current available drugs. Today, over 500 million men suffer from these sexual dysfunctions and the market is valued at USD 8 billion. Dicot Pharma's business model involves evaluating industrial and financial partnerships during clinical development to bring LIB-01 to commercialization on the world market.

Dicot Pharma is listed on Nasdaq First North and has approximately 9,100 shareholders. FNCA Sweden AB is appointed Certified Adviser. For more information, please visit www.dicotpharma.com.

Attached files

Dicot_Pharma_Notice_to_AGM.pdf